RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma * Metastatic or recurrent disease * Not curable by standard therapies * Must have failed at least 1, but no more than 3, prior therapies for metastatic or recurrent disease * Patients with colorectal or breast adenocarcinoma must have failed at least 2 prior therapies * Must have had at least stable disease for 3 months while on last treatment prior to most recent disease progression * Meets 1 of the following criteria: * At least 1 measurable site of disease ≥ 2 cm by radiography * Evaluable disease that could be reliably and consistently followed, as deemed by the principal investigator * RAAG12 expression confirmed\* by immunohistochemistry NOTE: \*Not required for patients with colon, pancreatic, or gastric adenocarcinoma * No evidence of residual or recurrent CNS metastases * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age * 18 and over Sex * Not specified Menopausal status * Not specified Performance status * ECOG 0-1 Life expectancy * More than 3 months Hematopoietic * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL (transfusions allowed) * Absolute neutrophil count ≥ 1,500/mm\^3 Hepatic * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * γ-glutamyl transferase ≤ 2.5 times ULN * Adequate hepatic function sufficient to undergo study therapy Renal * Creatinine \< 1.5 mg/d…